Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Import"

1805 News Found

Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis
R&D | October 30, 2025

Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis

Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging


FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes
Drug Approval | October 29, 2025

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms


Akums breaks ground for its first overseas manufacturing facility in Zambia
News | October 28, 2025

Akums breaks ground for its first overseas manufacturing facility in Zambia

It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products


ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission
R&D | October 27, 2025

ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission

With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market


Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
News | October 27, 2025

Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion

The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year


Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors
Clinical Trials | October 25, 2025

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile


Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP
News | October 23, 2025

Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA


Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV
News | October 23, 2025

Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients


Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Clinical Trials | October 23, 2025

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile


FDA approves Roche’s kidney inflammation drug
Drug Approval | October 22, 2025

FDA approves Roche’s kidney inflammation drug

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study